230 related articles for article (PubMed ID: 26427456)
1. Evaluation of Ocular Gene Therapy in an Italian Patient Affected by Congenital Leber Amaurosis Type 2 Treated in Both Eyes.
Testa F; Maguire AM; Rossi S; Marshall K; Auricchio A; Melillo P; Bennett J; Simonelli F
Adv Exp Med Biol; 2016; 854():533-9. PubMed ID: 26427456
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.
Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW
Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650
[TBL] [Abstract][Full Text] [Related]
3. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy.
Weleber RG; Pennesi ME; Wilson DJ; Kaushal S; Erker LR; Jensen L; McBride MT; Flotte TR; Humphries M; Calcedo R; Hauswirth WW; Chulay JD; Stout JT
Ophthalmology; 2016 Jul; 123(7):1606-20. PubMed ID: 27102010
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for eye as regenerative medicine? Lessons from RPE65 gene therapy for Leber's Congenital Amaurosis.
Rakoczy EP; Narfström K
Int J Biochem Cell Biol; 2014 Nov; 56():153-7. PubMed ID: 25286304
[TBL] [Abstract][Full Text] [Related]
5. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2.
Testa F; Maguire AM; Rossi S; Pierce EA; Melillo P; Marshall K; Banfi S; Surace EM; Sun J; Acerra C; Wright JF; Wellman J; High KA; Auricchio A; Bennett J; Simonelli F
Ophthalmology; 2013 Jun; 120(6):1283-91. PubMed ID: 23474247
[TBL] [Abstract][Full Text] [Related]
6. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.
Pennesi ME; Weleber RG; Yang P; Whitebirch C; Thean B; Flotte TR; Humphries M; Chegarnov E; Beasley KN; Stout JT; Chulay JD
Hum Gene Ther; 2018 Dec; 29(12):1428-1437. PubMed ID: 29869534
[TBL] [Abstract][Full Text] [Related]
7. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.
Simonelli F; Maguire AM; Testa F; Pierce EA; Mingozzi F; Bennicelli JL; Rossi S; Marshall K; Banfi S; Surace EM; Sun J; Redmond TM; Zhu X; Shindler KS; Ying GS; Ziviello C; Acerra C; Wright JF; McDonnell JW; High KA; Bennett J; Auricchio A
Mol Ther; 2010 Mar; 18(3):643-50. PubMed ID: 19953081
[TBL] [Abstract][Full Text] [Related]
9. Seeing is believing: gene therapy shows promise for ocular disorders.
Friedrich MJ
JAMA; 2010 Oct; 304(14):1543-5. PubMed ID: 20940376
[No Abstract] [Full Text] [Related]
10. Long-term effect of gene therapy on Leber's congenital amaurosis.
Bainbridge JW; Mehat MS; Sundaram V; Robbie SJ; Barker SE; Ripamonti C; Georgiadis A; Mowat FM; Beattie SG; Gardner PJ; Feathers KL; Luong VA; Yzer S; Balaggan K; Viswanathan A; de Ravel TJ; Casteels I; Holder GE; Tyler N; Fitzke FW; Weleber RG; Nardini M; Moore AT; Thompson DA; Petersen-Jones SM; Michaelides M; van den Born LI; Stockman A; Smith AJ; Rubin G; Ali RR
N Engl J Med; 2015 May; 372(20):1887-97. PubMed ID: 25938638
[TBL] [Abstract][Full Text] [Related]
11. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year.
Cideciyan AV; Hauswirth WW; Aleman TS; Kaushal S; Schwartz SB; Boye SL; Windsor EA; Conlon TJ; Sumaroka A; Pang JJ; Roman AJ; Byrne BJ; Jacobson SG
Hum Gene Ther; 2009 Sep; 20(9):999-1004. PubMed ID: 19583479
[TBL] [Abstract][Full Text] [Related]
12. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.
Cideciyan AV; Jacobson SG; Beltran WA; Sumaroka A; Swider M; Iwabe S; Roman AJ; Olivares MB; Schwartz SB; Komáromy AM; Hauswirth WW; Aguirre GD
Proc Natl Acad Sci U S A; 2013 Feb; 110(6):E517-25. PubMed ID: 23341635
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy.
Yang S; Ma SQ; Wan X; He H; Pei H; Zhao MJ; Chen C; Wang DW; Dong XY; Yuan JJ; Li B
EBioMedicine; 2016 Aug; 10():258-68. PubMed ID: 27426279
[TBL] [Abstract][Full Text] [Related]
14. Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.
Gange WS; Sisk RA; Besirli CG; Lee TC; Havunjian M; Schwartz H; Borchert M; Sengillo JD; Mendoza C; Berrocal AM; Nagiel A
Ophthalmol Retina; 2022 Jan; 6(1):58-64. PubMed ID: 33838313
[TBL] [Abstract][Full Text] [Related]
15. Treatment Potential for LCA5-Associated Leber Congenital Amaurosis.
Uyhazi KE; Aravand P; Bell BA; Wei Z; Leo L; Serrano LW; Pearson DJ; Shpylchak I; Pham J; Vasireddy V; Bennett J; Aleman TS
Invest Ophthalmol Vis Sci; 2020 May; 61(5):30. PubMed ID: 32428231
[TBL] [Abstract][Full Text] [Related]
16. The Status of RPE65 Gene Therapy Trials: Safety and Efficacy.
Pierce EA; Bennett J
Cold Spring Harb Perspect Med; 2015 Jan; 5(9):a017285. PubMed ID: 25635059
[TBL] [Abstract][Full Text] [Related]
17. Pseudo-fovea formation after gene therapy for RPE65-LCA.
Cideciyan AV; Aguirre GK; Jacobson SG; Butt OH; Schwartz SB; Swider M; Roman AJ; Sadigh S; Hauswirth WW
Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):526-37. PubMed ID: 25537204
[TBL] [Abstract][Full Text] [Related]
18. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.
Stein L; Roy K; Lei L; Kaushal S
Expert Opin Biol Ther; 2011 Mar; 11(3):429-39. PubMed ID: 21299439
[TBL] [Abstract][Full Text] [Related]
19. Spectral sensitivity measurements reveal partial success in restoring missing rod function with gene therapy.
Ripamonti C; Henning GB; Robbie SJ; Sundaram V; van den Born LI; Casteels I; de Ravel TJ; Moore AT; Smith AJ; Bainbridge JW; Ali RR; Stockman A
J Vis; 2015; 15(15):20. PubMed ID: 26605849
[TBL] [Abstract][Full Text] [Related]
20. The Role of the Human Visual Cortex in Assessment of the Long-Term Durability of Retinal Gene Therapy in Follow-on RPE65 Clinical Trial Patients.
Ashtari M; Nikonova ES; Marshall KA; Young GJ; Aravand P; Pan W; Ying GS; Willett AE; Mahmoudian M; Maguire AM; Bennett J
Ophthalmology; 2017 Jun; 124(6):873-883. PubMed ID: 28237426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
